Home Federal Bank of Tennessee Sells 425 Shares of Pfizer Inc. (NYSE:PFE)

Home Federal Bank of Tennessee reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,304 shares of the biopharmaceutical company’s stock after selling 425 shares during the quarter. Home Federal Bank of Tennessee’s holdings in Pfizer were worth $724,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management grew its stake in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 1.5 %

PFE opened at $26.51 on Monday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.66 and a beta of 0.64. The stock has a fifty day moving average of $26.27 and a 200-day moving average of $27.85.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.